The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

14 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of Selective Small-Molecule Inhibitors for theß-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety.EBI
University of Utah
Hot spot-based design of small-molecule inhibitors for protein-protein interactions.EBI
University of Utah
Direct targeting ofß-catenin: Inhibition of protein-protein interactions for the inactivation of Wnt signaling.EBI
Chemical Genomics Centre of The Max Planck Society
Design, synthesis, and biological evaluation of novel 8-substituted quercetin derivatives targeting the β‑catenin/B-cell lymphoma 9 interaction.EBI
Tongji University
Design, synthesis and biological evaluation of quercetin derivatives as novel β-catenin/B-cell lymphoma 9 protein-protein interaction inhibitors.EBI
Fudan University
Recent advances of β-catenin small molecule inhibitors for cancer therapy: Current development and future perspectives.EBI
Sichuan University
Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer.EBI
Fudan University
Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.EBI
Ocean University of China
Targeting the interaction of β-catenin and TCF/LEF transcription factors to inhibit oncogenic Wnt signaling.EBI
Vu University Amsterdam
Biophysical Survey of Small-Molecule β-Catenin Inhibitors: A Cautionary Tale.EBI
University of Southampton
Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.EBI
H. Lee Moffitt Cancer Center and Research Institute
Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide.EBI
The Ohio State University
Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.EBI
H. Lee Moffitt Cancer Center and Research Institute
Substituted B-amino acid derivatives as CXCR3 receptor antagonistsBDB
Sanofi